New analyses from five landmark trials of Enhertu® and Datroway® in breast and gastric cancer alongside pipeline data across other tumor types demonstrate continued oncology leadership
Early phase trials-in-progress featuring potential medicines with novel mechanisms highlight the company’s commitment to identifying new breakthrough generating technologies for patients with cancer
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26).
Data at ASCO will highlight the company’s progress toward advancing new standards of care for patients with cancer, including new analyses from five landmark trials in breast and gastric cancer, including the
DESTINY-Breast05
(#
516
),
DESTINY-Breast06
(#
1063
),
DESTINY-Breast09
(#
1021
) and
DESTINY-Gastric04
(#
4111
) phase 3 trials of Enhertu
®
(trastuzumab deruxtecan), and the
TROPION-Breast02
(#
1002
) phase 3 trial of Datroway
®
(datopotamab deruxtecan). Additional results from earlier phase trials as well as trials-in-progress across new medicines being developed through the company’s breakthrough generating technology (BGT), a platform-based drug discovery model designed to deliver innovative medicines to patients faster, will be highlighted.
Data from
DESTINY-Breast05
formed the basis of one of two new Enhertu indications recently
approved
in the U.S. for certain patients with early-stage HER2 positive breast cancer and data from
DESTINY-Gastric04
was included as part of a label update to expand the use of Enhertu in
Japan
and
China
to include the second-line treatment of patients with HER2 positive metastatic gastric cancer. Additionally, results from
TROPION-Breast02
formed the basis of the recent
U.S. approval
of Datroway in patients with metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy, the first antibody drug conjugate (ADC) to be approved in this setting of TNBC.
“The approvals received just prior to ASCO for Enhertu and Datroway, two of our leading DXd antibody drug conjugates, together with the strong science being showcased across our pipeline, highlight the momentum of our oncology portfolio,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “Daiichi Sankyo is committed to creating new standards of care for patients with cancer and continues to leverage its scientific and technological expertise to advance innovation.”
Additional Enhertu Data Spans Broad Range of HER2 Expressing Cancers
Additional research updates across several additional HER2 expressing cancers include oral and poster sessions highlighting the preliminary safety run-in results from the
DESTINY-Ovarian01
(#
5554
) phase 3 trial evaluating Enhertu in combination with bevacizumab compared to bevacizumab monotherapy as a first-line maintenance therapy in patients with HER2 expressing ovarian cancer; the primary analysis from part 1 of the
DESTINY-PanTumor03
(#
3026
) phase 2 trial evaluating Enhertu in pretreated patients in China with HER2 positive (IHC 3+) solid tumors (excluding breast and gastric cancer); and, findings from the
MYTHOS
(#
6011
) phase 2 trial evaluating Enhertu in patients with HER2-low recurrent or metastatic salivary gland cancer.
Additional breast and gastric cancer data for Enhertu include an oral presentation from one arm of the
DESTINY-Breast07
(#
1012
) phase 1b/2 trial evaluating Enhertu in combination with durvalumab as a first-line treatment in patients with HER2 positive metastatic breast cancer and a poster presentation highlighting a safety analysis from the
DESTINY-Gastric03
(#
4022
) phase 1b/2 trial evaluating Enhertu in combination with chemotherapy and immunotherapy as a first-line treatment in patients with HER2 expressing metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma or esophageal adenocarcinoma.
Results from cohort two of the
EPOC2203
(#
4024
) phase 1b/2 trial evaluating Enhertu in combination with nivolumab and capecitabine and oxaliplatin in patients with HER2 low gastroesophageal adenocarcinoma and an exploratory analysis of translational data from the
EPOC2003
(#
3129
) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer will be highlighted as poster presentations.
New Data and Trials-in-Progress Presentations Across Oncology Portfolio
Poster presentations will include a trial-in-progress update of
REJOICE-Ovarian01
(
TPS5637
) for the phase 3 part of a phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) compared to treatment of physician’s choice in patients with platinum-resistant ovarian cancer. Two additional poster presentations will highlight an exposure-response analysis (#
5570
) and a population pharmacokinetic analysis (#
5571
) of data from both the
REJOICE-Ovarian01
phase 2/3 trial and the
phase 1 trial
evaluating raludotatug deruxtecan in patients with advanced ovarian cancer or renal cell carcinoma.
An oral presentation will highlight results from a
phase 1/2 trial
(#
6504
) of Vanflyta® (quizartinib) plus decitabine and venetoclax in patients with newly diagnosed or relapsed/refractory
FLT3
-ITD acute myeloid leukemia.
Trials-in-progress poster presentations across the DXd ADC portfolio include the
TROPION-Urothelial03
(
TPS4642
) phase 2/3 trial evaluating Datroway and platinum chemotherapy compared to gemcitabine plus platinum chemotherapy in patients with locally advanced or metastatic urothelial carcinoma; the
HERTHENA-Breast04
(
TPS1149
) phase 3 trial evaluating patritumab deruxtecan (HER3-DXd) compared to treatment of physician’s choice in patients with HR positive, HER2 negative unresectable locally advanced or metastatic breast cancer; and the
DESTINY-PanTumor04
(
TPS11202
) hybrid observational trial evaluating Enhertu in patients with HER2 positive (IHC 3+) solid tumors.
Trials-in-Progress Presentations Highlight Breakthrough Generating Technology Focus
Daiichi Sankyo is leveraging its strength in science and technology to create new medicines for patients with cancer through its BGT approach which is designed to deliver innovative medicines to patients faster and with a higher probability of success. Trials-in-progress poster presentations featuring three potential new medicines include
DS3610
(
TPS3159
), a STING (stimulator of interferon genes) ADC, in patients with advanced or metastatic solid tumors;
DS5361
(
TPS2680
), a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced or metastatic solid tumors; and,
DS9051
(
TPS3179
), a novel targeted protein degradation molecule, in patients with advanced or metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer.
Overview of clinical data and trials-in-progress from oncology pipeline of Daiichi Sankyo include:
Presentation Title
Author
Abstract
Presentation (CDT)
Breast
A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab
Y. Park
1021
Rapid Oral Presentation
Sunday, May 31
11:30 am – 1:00 pm
Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: clinical and demographic risk factors of interstitial lung disease and radiation pneumonitis
M. Untch
516
Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial
C. O’Sullivan
LBA514
Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am
Trastuzumab deruxtecan (T-DXd) + durvalumab in patients with previously untreated HER2 positive unresectable/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07
S. Loi
1012
Oral Presentation
Sunday, May 31
8:30 – 10:00 am
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: additional efficacy endpoints from the TROPION-Breast02 study
D. Cescon
1002
Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm
Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines on ILD/pneumonitis outcomes: a retrospective analysis of patients treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06
C. Mateo
1063
Poster Session
Monday, June 1
1:30 – 4:30 pm
HERTHENA-Breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor positive (HR +)/HER2-) unresectable locally advanced or metastatic breast cancer
B. Pistilli
TPS1149
Poster Session
Monday, June 1
1:30 – 4:30 pm
Identifying patients with human epidermal growth factor receptor 2 (HER2) low and ultralow breast cancer: use of digital, artificial intelligence-based computational algorithms to assist HER2 scoring by pathologists
S. Krishnamurthy
1022
Poster Session
Monday, June 1
1:30 – 4:30 pm
Gastric
Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab + paclitaxel in patients with HER2 positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma
K. Shitara
4111
Poster Session
Saturday, May 30
9:00 am – 12:00 pm
First-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2 expressing gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4
Y. Janjigian
4022
Poster Session
Saturday, May 30
9:00 am – 12:00 pm
An open-label phase 1b/2 study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2 low gastroesophageal adenocarcinoma (EPOC2203)
Y. Aoki
4024
Poster Session
Saturday, May 30
9:00 am – 12:00 pm
Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2 positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study
A. Kawazoe
3129
Poster Session
Saturday, May 30
1:30 – 4:30 pm
Ovarian
Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients with HER2 expressing ovarian cancer: results from the DESTINY-Ovarian01 safety run-in
A. Gonzalez Martin
5554
Poster Session
Monday, June 1
9:00 am – 12:00 pm
REJOICE-Ovarian01: phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer
D. Richardson
TPS5637
Poster Session
Monday, June 1
9:00 am – 12:00 pm
Exposure-response analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, to inform dose selection for phase 3 development in platinum-resistant ovarian cancer
F. Hurtado
5570
Poster Session
Monday, June 1
9:00 am – 12:00 pm
Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, in patients with advanced ovarian cancer or renal cell carcinoma
F. Hurtado
5571
Poster Session
Monday, June 1
9:00 am – 12:00 pm
Urothelial
TROPION-Urothelial03: a phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy vs gemcitabine + platinum chemotherapy in participants with locally advanced or metastatic urothelial carcinoma with progression on or after enfortumab vedotin + pembrolizumab
M. Galsky
TPS4642
Poster Session
Sunday, May 31
9:00 am – 12:00 pm
Salivary
Trastuzumab deruxtecan in patients with HER2 low recurrent/metastatic salivary gland carcinoma: results from the phase 2 MYTHOS trial
I. Kinoshita
6011
Oral Presentation
Monday, June 1
8:00 – 9:30 am
AML
Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory
FLT3
mutated acute myeloid leukemia
M. Yilmaz
6504
Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm
Pan Tumor
Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis
Y. Zhang
3026
Poster Session
Saturday, May 30
1:30 – 4:30 pm
A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC3+ solid tumors: DESTINY-PanTumor04
B. Monk
TPS11202
Poster Session
Monday, June 1
9:00 am – 12:00 pm
HER2 independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors
S. Shin
3031
Poster Session
Saturday, May 30
1:30 – 4:30 pm
Topoisomerase 1 and DNA damage: pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors
D. Wilsker
3092
Poster Session
Saturday, May 30
1:30 – 4:30 pm
BGT
A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist ADC, in patients with advanced/metastatic solid tumors
S. Koganemaru
TPS3159
Poster Session
Saturday, May 30
1:30 – 4:30 pm
A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced/metastatic solid tumors (Parts 1 and 2)
S. Sen
TPS2680
Poster Session
Saturday, May 30
1:30 – 4:30 pm
A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer
M. Patel
TPS3179
Poster Session
Saturday, May 30
1:30 – 4:30 pm
About the ADC Portfolio of Daiichi Sankyo
The Daiichi Sankyo ADC portfolio consists of eight ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo.
The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo.
An additional ADC being developed by Daiichi Sankyo is DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING.
Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610 and DS3790 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi Sankyo
Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit
.
Contacts
MEDIA CONTACTS:
Global:
Jennifer Brennan
jennifer.brennan@daiichisankyo.com
+1 908 900 3183 (mobile)
Japan:
DS-PR_jp@daiichisankyo.com
INVESTOR RELATIONS CONTACT:
DaiichiSankyoIR_jp@daiichisankyo.com
